Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Rejuveinix (RJX) in Healthy Participants
NCT03680105Phase 1Completed
- Sponsor
- Reven Pharmaceuticals
- Start
- Aug 2018
- Primary completion
- Jan 2019
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rejuveinix in critical limb ischemia (CLI) (9 cohorts), sponsored by Reven Pharmaceuticals. Primary endpoints: Treatment-related Adverse Events, Safety and Tolerability of RJX as Assessed by Electrocardiograms and 1 more. Started Aug 2018; status: completed.
02
Drugs
rejuveinix
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT03680105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03680105.